Pharmaron Beijing Co., Ltd. Announces Major RMB2 Billion Investment Agreement for Hangzhou CDMO Facility
Key Highlights
- Pharmaron Beijing Co., Ltd. (“Pharmaron” or “the Company”) has signed an investment agreement with Hangzhou Qiantang Investment Service Center to construct a new drug commercialisation production and CDMO (Contract Development and Manufacturing Organization) R&D facility in the Qiantang District, Hangzhou.
- The estimated total investment for the Hangzhou Project amounts to approximately RMB2.0 billion, with the facility expected to be operational by 2029.
- The project is intended to further expand Pharmaron’s production capacity for innovative drug commercial manufacturing, strengthen integrated service capability for new drug modalities, and consolidate the Company’s core business foundation.
- Pharmaron will establish a wholly-owned subsidiary, Pharmaron (Hangzhou) API Manufacturing Co., Ltd., to operate and manage the new facility.
- The investment agreement was approved by the Board on May 26, 2026, and signed on May 27, 2026.
Detailed Investment Overview
The Hangzhou Project will be located in the Linjiang Area of Qiantang District, covering approximately 200 mu of land. The investment will cover land acquisition, construction costs, and other related expenses. Pharmaron Hangzhou, the new subsidiary, will be responsible for all aspects of investment, construction, and operation. No definitive capital commitment agreements have been signed as of the announcement date, and no cash consideration is payable between Pharmaron and Qiantang Investment Center under this investment agreement.
Importantly, if Pharmaron fails to successfully bid for the land required, the investment agreement will automatically terminate, with neither party bearing any responsibility or obligation.
Strategic Significance and Potential Impact
- The Hangzhou Project is strategically designed to enhance Pharmaron’s capabilities in small molecule and new drug modality commercial manufacturing and CDMO services. This will support the efficient conversion of CDMO service pipelines toward late-stage clinical trial and commercialisation.
- The Company aims to accelerate its strategic objectives and cultivate new growth drivers for sustainable development, expanding market share and strengthening its integrated service platform across multiple drug modalities.
- The project is not expected to have a material impact on the Company’s financial position or operating results for the year ending December 31, 2026, but could significantly affect future profitability and growth depending on construction progress and order situation.
Risks and Cautions for Shareholders
- The pharmaceutical industry is subject to uncertainties from policy changes, market environment, and medication demand, which could impact drug production and sales.
- The project requires multiple approvals (feasibility, environmental, planning, construction) from competent authorities and may face risks of delay, modification, suspension, or termination.
- The large investment scale means funding sources, capital raising, and construction progress could be influenced by macroeconomic conditions and credit policies.
- Shareholders and potential investors are advised to exercise caution and pay close attention to future disclosures regarding the Hangzhou Project’s progress.
Regulatory and Disclosure Notes
The transactions under the investment agreement do not constitute notifiable transactions under Chapter 14 of the Hong Kong Listing Rules, as applicable percentage ratios are all less than 5%. This announcement is made voluntarily, and further announcements will be issued as appropriate and required under the Listing Rules.
Management Statement
Dr. Lou Boliang, Chairman, emphasizes the Hangzhou Project’s role in advancing Pharmaron’s long-term strategic objectives, promoting business development, and enhancing profitability. The Board comprises a mix of executive, non-executive, employee representative, and independent directors.
Conclusion
Pharmaron’s RMB2.0 billion investment in the Hangzhou CDMO facility represents a significant strategic move that could influence future share value, particularly as the project progresses and begins operations. While not immediately impacting 2026 financial results, its long-term implications for capacity, competitiveness, and market position are potentially price-sensitive and noteworthy for investors.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research and consult professional advisors before making any investment decisions. The information herein is based on publicly available disclosures as of May 27, 2026, and may be subject to further updates.
和黃藥明（Pharmaron Beijing）宣佈杭州CDMO研發生產設施重大投資協議
重點摘要
- 和黃藥明（Pharmaron）與杭州錢塘投資服務中心簽訂投資協議，計劃於杭州錢塘區建設一個新藥商業化生產及CDMO研發設施。
- 杭州項目預計總投資約20億人民幣，該設施預計於2029年投入運營。
- 此項目旨在擴大公司創新藥商業生產及CDMO服務產能，提升新藥模式項目綜合服務能力，鞏固核心業務基礎。
- 公司將設立全資子公司——和黃藥明（杭州）API製造有限公司——負責該新設施的運營管理。
- 投資協議已於2026年5月26日董事會批准，並於2026年5月27日簽訂。
投資詳情
杭州項目選址於錢塘區臨江地區，佔地約200畝。投資包括土地收購、建設費用及相關成本。新子公司將全權負責投資、建設及運營。至公告日期，公司尚未簽訂具體資金承諾協議，且投資協議下公司與錢塘投資中心間無現金對價。
值得注意的是，如公司未能成功競標所需土地，投資協議將自動終止，雙方互不承擔責任。
戰略意義及潛在影響
- 該項目旨在提升公司小分子及新藥模式商業生產及CDMO服務能力，推動CDMO服務項目管線向後期臨床及商業化轉化。
- 公司希望加速戰略目標實現，培育可持續發展新動力，擴大市場份額並強化多模式一體化服務平台。
- 該項目預期不會對2026全年財務狀況或業績造成重大影響，但隨著項目進展及訂單情況，未來盈利增長潛力巨大。
股東須知風險提示
- 製藥行業受政策、市場環境及藥品需求影響，存在不確定性。
- 項目需獲得多項審批，包括可行性、環保、規劃、建設等，可能面臨延期、修改、暫停或終止風險。
- 大規模投資意味著資金來源及建設進度可能受宏觀經濟及信貸政策影響。
- 股東及潛在投資者應保持警惕，密切留意公司後續公告。
監管及披露事項
根據香港上市規則第14章，投資協議下適用百分比比率均低於5%，不構成須通報交易。本公告屬自願性，若有進展將按規則適時披露。
管理層聲明
主席樓伯良博士強調，杭州項目將推動公司長遠戰略目標，促進業務發展及盈利能力提升。董事會成員涵蓋執行、非執行、員工代表及獨立董事。
總結
和黃藥明於杭州CDMO設施投入20億人民幣，為公司未來產能、競爭力及市場地位帶來重大發展潛力，或對股價構成影響。雖短期財務未見重大變化，但長遠價值值得股東關注。
免責聲明
本文章僅供參考，不構成投資建議。投資者應自行研究並諮詢專業顧問。本資料根據2026年5月27日公開公告整理，後續或有更新。
